A client with arterial insufficiency presents with a small, necrotic open area on the outer aspect of the right great toe. There is no drainage present and the client states that leg cramps at night have caused disrupted sleep. What is the priority nursing action?

A. Arterial ulcers: These wounds typically occur on distal points such as the toes or the dorsal aspect of the foot due to poor tissue perfusion. A hallmark sign is "rest pain" that worsens with elevation, as gravity no longer assists blood flow to the extremities. They often appear dry or "punched out" without significant exudate.

B. Diabetic foot ulcers: While these occur on the feet, they are primarily associated with peripheral neuropathy and occur on pressure-bearing plantigrade surfaces. The pain reported with elevation is more characteristic of macrovascular arterial disease than pure diabetic neuropathy. Neuropathic ulcers are often painless due to the loss of sensory perception.

C. Venous stasis ulcers: These ulcers are usually located near the medial malleolus and are characterized by irregular borders and significant edema. Unlike arterial ulcers, the pain associated with venous disease is typically relieved by elevation, which promotes venous return. They are also highly exudative, which contradicts the "without exudate" assessment.

D. Stage two pressure injuries: These involve partial-thickness loss of the dermis and are caused by sustained mechanical pressure over bony prominences. The dorsal foot and medial toe are less common sites for pressure injuries unless caused by ill-fitting footwear. The specific pain pattern with elevation strongly points toward a vascular rather than a mechanical etiology.

A. "The patch will work quickly and effectively to manage your pain.": Transdermal patches have a slow onset of action, often taking 12 to 24 hours to reach therapeutic steady-state levels. Promising a "quick" result is medically inaccurate and mismanages the client's expectations for relief. Patches are designed for long-term maintenance rather than rapid acute analgesia.

B. "The patch will give you a longer duration of pain relief especially during sleep.": While true that patches provide long-acting relief, this statement does not address the client's primary concern about adequacy or previous dissatisfaction with sedation. It fails to explain the pharmacokinetic advantage of consistent dosing over intermittent oral boluses. It provides incomplete education regarding the transition.

C. "The patch has creams and oils imbedded in it to prevent friction and shearing which can lead to skin breakdown.": This is a physiological falsehood regarding the construction of transdermal delivery systems. Patches contain a drug reservoir and an adhesive, but they are not designed as skin-protective barriers against mechanical shearing. Their purpose is systemic drug delivery, not localized dermatological protection.

D. "The patch will maintain consistent levels of the drug in your blood. We may be able to supplement with another pain medication until pain control is reached.": Continuous delivery avoids the "peaks" and "troughs" associated with oral meds, which often cause excessive sedation at peak and pain at trough. Informing the client about supplemental "breakthrough" medication provides a safety net during the slow onset period of the transdermal system.